MedinCell S.A. has recently reached the commercial stage with the market launch by Teva of UZEDY? for the treatment of schizophrenia. UZEDY is the first innovative product based on MedinCell?s long-acting injectable (LAI) BEPO® technology approved by US FDA.

Teva recently provided the annual revenue guidance for UZEDY, projecting approximately $80 millionfor 2024. This revenue estimate is in line with MedinCell's anticipated earnings from UZEDY, as the company is set to receive royalties from sales and could earn up to $105 million in commercial milestones. In parallel, MedinCell is developing a portfolio of innovative treatments also using the BEPO technology.

Candidates in clinical Phase 3: mdc-TJK (partnership with Teva): Potentially, the first long-acting injectable olanzapine with a favorable safety profile that could enable a large adoption for treatment of patients with more severe forms of schizophrenia mdc-CWM (partnership with AIC): An innovative sustained-release formulation of a non-steroidal anti-inflammatory drug celecoxib aiming at facilitating patient recovery after total knee replacement and decreasing the need for potentially addictive opioids. Other programs are currently in the evaluation, formulation or preclinical stage, some as part of the internal program development strategy, others within the framework of partnerships.